52Q Stock Overview
A diagnostic company, develops and commercializes tests for monitoring and optimizing the dosage of biological drugs Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
AegirBio AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.049 |
| 52 Week High | kr0.16 |
| 52 Week Low | kr0.037 |
| Beta | 2.66 |
| 1 Month Change | -0.81% |
| 3 Month Change | -20.16% |
| 1 Year Change | -65.66% |
| 3 Year Change | -99.39% |
| 5 Year Change | n/a |
| Change since IPO | -95.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 52Q | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 23.1% | 0.4% | 0.6% |
| 1Y | -65.7% | -23.7% | 5.4% |
Return vs Industry: 52Q underperformed the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 52Q underperformed the German Market which returned 7.3% over the past year.
Price Volatility
| 52Q volatility | |
|---|---|
| 52Q Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 52Q's share price has been volatile over the past 3 months.
Volatility Over Time: 52Q's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 13 | Marco Wititteveen | aegirbio.com |
AegirBio AB (publ), a diagnostic company, develops and commercializes tests for monitoring and optimizing the dosage of biological drugs Sweden and internationally. The company focuses on the neurology, oncology, and autoimmune therapeutic areas. It offers moNATor, a first dose-monitoring laboratory test that provides multiple sclerosis for healthcare professionals and patients; and Viraspec, a COVID-19 saliva test kit.
AegirBio AB (publ) Fundamentals Summary
| 52Q fundamental statistics | |
|---|---|
| Market cap | €1.64m |
| Earnings (TTM) | -€5.13m |
| Revenue (TTM) | €7.90k |
207.4x
P/S Ratio-0.3x
P/E RatioIs 52Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 52Q income statement (TTM) | |
|---|---|
| Revenue | kr92.00k |
| Cost of Revenue | kr48.00k |
| Gross Profit | kr44.00k |
| Other Expenses | kr59.74m |
| Earnings | -kr59.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.93 |
| Gross Margin | 47.83% |
| Net Profit Margin | -64,886.96% |
| Debt/Equity Ratio | -2,237.9% |
How did 52Q perform over the long term?
See historical performance and comparison